News
Texas sues, accusing Eli Lilly of 'bribing' physicians to prescribe Zepbound, Mounjaro and other drugs
Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as administrative support services that helped providers process insurance claims.
Texas Sues Eli Lilly: 'Big Pharma Compromised Medical Decision-Making'
Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its most profitable drugs, including the high-demand GLP-1 medications Mounjaro and Zepbound that are used for weight loss and diabetes treatment.
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Hosted on MSN11mon
Eli Lilly Just Made Zepbound Even More Appealing. Here's What ... - MSN
Per a recent press release, Lilly is now offering a four-week supply of 2.5 milligram Zepbound vials for $399, as well as a 5 mg dose for $549.
Lilly has priced Zepbound at about $1,060 for a month’s supply, and while it’s less than Wegovy, which is priced at around $1,300, both drugs may be too expensive for many people who are eligible.
News provided by Eli Lilly and Company Jun 16, 2025, 6:45 AM ET With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month ...
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.
Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback